(Q44444418)

English

Gastrointestinal transit and release of 5‐aminosalicylic acid from 153Sm‐labelled mesalazine pellets vs. tablets in male healthy volunteers

scientific article published on May 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Gastrointestinal transit and release of 5‐aminosalicylic acid from 153Sm‐labelled mesalazine pellets vs. tablets in male healthy volunteers (English)

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

author name string

M. Brunner

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752353

3 January 2024

R. Greinwald

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752353

3 January 2024

K. Kletter

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752353

3 January 2024

H. Kvaternik

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752353

3 January 2024

M. E. Corrado

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752353

3 January 2024

H. G. Eichler

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752353

3 January 2024

M. Müller

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752353

3 January 2024

language of work or name

0 references

publication date

1 May 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

full work available at URL

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2036.2003.01564.x

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752353

3 January 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2036.2003.01564.x

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.2003.01564.x

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1163-1169

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01564.X

21 January 2018

Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

1

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease

2

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Clinical pharmacokinetics of slow release mesalazine

3

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Absorption, metabolism, and excretion of salicylazosulfapyridine in man

6

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease

7

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Evaluation of an enteric-coated naproxen pellet formulation

10

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy

11

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Gamma scintigraphy in the evaluation of pharmaceutical dosage forms

12

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Colonic transit scintigraphy. A physiologic approach to the quantitative measurement of colonic transit in humans.

13

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Correlation of ibuprofen bioavailability with gastrointestinal transit by scintigraphic monitoring of 171Er-labeled sustained-release tablets

14

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Gastrointestinal transit and systemic absorption of captopril from a pulsed-release formulation

16

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Simultaneous determination of 5-aminosalicylic acid and 5-acetylaminosalicylic acid by high-performance liquid chromatography

17

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Simplified high-performance liquid chromatographic method for 5-aminosalicylic acid in plasma and urine

18

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

19

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion

23

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease

24

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Gastrointestinal transit of an enteric-coated delayed-release 5-aminosalicylic acid tablet

25

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Oroileal transit of slow release 5-aminosalicylic acid

26

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Delivery and fate of oral mesalamine microgranules within the human small intestine

27

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease

28

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

29

1 reference

10.1046/J.1365-2036.2003.01564.X

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01564.X

3 January 2024

Identifiers

10.1046/J.1365-2036.2003.01564.X

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44444418&oldid=2046247508"